ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1069

CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis

Alisa Mueller1, Andrea Fava 2, Deepak Rao 1 and Francesco Boin 3, 1Brigham and Women's Hospital, Boston, MA, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3UCSF, San Francisco, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: fibrosis and Science, Scleroderma, Systemic sclerosis, T cells

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by tissue fibrosis, vascular injury, and autoantibody production. CXCR5+ PD-1+ T follicular helper (Tfh) cells, which are T cells specialized to help B cells, are expanded in the circulation of SSc patients and may contribute to both immune activation and fibrotic organ damage. Emerging evidence supports the existence of a wider range of B cell-helper T cells characterized by high expression of PD-1 including PD-1hi CXCR5– T peripheral helper (Tph) cells, which are dramatically expanded in the joints of RA patients and in the circulation of SLE patients. Here, we have evaluated the frequency of PD-1hi CD4+ T cell subsets in a well-characterized cohort of SSc patients.

Methods: Peripheral blood mononuclear cells (PBMCs) were collected from 101 SSc patients fulfilling the 2013 ACR/EULAR SSc classification criteria and 33 healthy controls. A comprehensive set of demographic and clinical characteristics was obtained at the time of enrollment including data on organ involvement, disease severity, autoantibody profile, pulmonary and cardiac functional status, and medications. Flow cytometry analysis was performed on PBMCs using an antibody panel designed to identify specific CD4+ T cell subsets. Serum cytokine levels were measured by ELISA.

Results: Using strict gating on cells with very high PD-1 expression, we observed that the frequency of PD-1hi CD4+ T cells among total CD4+ T cells was significantly increased in SSc patients compared to healthy controls (0.136% vs. 0.078%, p = 0.0071; Figure 1A). The PD-1hi CD4+ population contains two distinct B cell-helper T cell subsets: CXCR5+ Tfh cells and CXCR5– Tph cells. Strict gating on CXCR5– cells indicated that PD-1hi CXCR5– Tph cells were also increased in SSc samples (p = 0.011). PD-1hi CD4+ T cell populations are the major source of the B cell chemoattractant CXCL13, and we observed a positive correlation between PD-1hi CD4+ T cell frequency and serum CXCL13 concentration in SSc patients (Spearman r = 0.33, p=0.017; Figure 1B). To evaluate clinical associations with PD-1hi CD4+ T cell frequency, we stratified SSc patients based on high (≥ 0.20%) or low (≤ 0.05%) PD-1hi CD4+ T cell frequency. We found that 58% (7/12) of patients with high PD-1hi CD4+ T cell numbers had interstitial lung disease (ILD) compared to 27% (4/15) of patients with low PD-1hi CD4+ T cell numbers.

Conclusion: Our study shows that the frequency of PD-1hi CD4+ T cells, including PD-1hi CXCR5– Tph cells, is significantly increased in SSc patients. Preliminary analyses suggest a relationship between PD-1hi CD4+ T cell frequency and SSc-ILD. These findings support a potential role for B cell-helper T cells including Tph cells in the autoimmune pathology of SSc.

Figure 1: Expanded PD-1hi CD4+ T cell population in SSc patients. A- Percentage of PD-1hi CD4+ T cells among total CD4+ T cells in PBMCs from SSc and control patients by flow cytometry. B- Correlation between frequency of PD-1hi CD4+ T cells and CXCL13 levels as measured by ELISA with Spearman statistics.


Disclosure: A. Mueller, None; A. Fava, None; D. Rao, Janssen, 5, Merck, 2, Pfizer, 5; F. Boin, None.

To cite this abstract in AMA style:

Mueller A, Fava A, Rao D, Boin F. CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cd4-t-helper-cell-populations-with-high-pd-1-expression-are-expanded-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd4-t-helper-cell-populations-with-high-pd-1-expression-are-expanded-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology